Skip to content

Multi-Center Randomized Clinical Study of Antidepressant treatment (fluoxetine) on Secondary Prevention of Ischemic Stroke

Multi-Center Randomized Clinical Study of Antidepressant treatment (fluoxetine) on Secondary Prevention of Ischemic Stroke

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002078
Enrollment
Unknown
Registered
2012-04-03
Start date
2011-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Interventions

target group:Fluoxetine and conventional therapy of cerebral infarction
controlled group:conventional therapy of cerebral infarction

Sponsors

Shenzhen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. In line with the ICD-10 acute cerebral infarction diagnostic criteria; 2. Aged 35 to 75 years; 3. 2 weeks after onset of cerebral infarction and exclude intracranial hemorrhage stroke by CT scan; 4. Written informed consent by patients or their family numbers.

Exclusion criteria

Exclusion criteria: 1. Massive cerebral infarcton or coma; 2. Pragnant or lactating woman; 3. Allergic; 4. Can not complete follow up of 1 year expected such as tsevere heart disease,cardiac insufficiency,hepatosis,renal inadequacy,respiratory failure,malignancy; 5. Gastrointestinal disdors that affecting drug absorption seriously; 6. Can not cooperate with the inspection such as severe speech dysfunction; 7. Psychopath; 8. Paticipate in other clinical trails.

Design outcomes

Primary

MeasureTime frame
Recurrence rate of cerebral infarction whin 3 month;

Secondary

MeasureTime frame
The improvement of hypertension, diabetes, hyperlipids;

Countries

China

Contacts

Public ContactGuo Yi
yi_g4326@yahoo.com.cn+86 13902978692

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026